Guggenheim Reiterates Buy on Allergan (AGN) Following Updated Guidance

Allergan (AGN) Receives FDA Approval to Market JUVEDERM ULTRA XC for Lip Augmentation

Allergan (NYSE: AGN) announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM® ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation.

"As the leader in medical aesthetics, Allergan is committed to continued research and development in this area," said Philippe Schaison, Executive Vice President & President, Allergan Medical.... More

RBC Capital Cuts Price Target on Allergan (AGN) Following 2H15 Guidance

RBC Capital maintained an Outperform rating on Allergen (NYSE: AGN), and cut the price target to $354.00 (from $375.00), after the company provided its anticipated 2H2015 "continuing operations" guidance. AGN provided 2H2015E revenue of >$8 billion, EBIT of $3.8 to $4.0 billion and EPS of $6.25 to $6.65.

Analyst Randall... More

Allergan forecasts second-half revenue above $8 billion

(Reuters) - Drugmaker Allergan Plc (NYSE: AGN) said it expected revenue to be greater than $8 billion in the second half as it completes the sale of its generics business to Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) (NYSE:... More

Nomura Securities Starts Allergen (AGN) at Buy

Nomura Securities initiates coverage on Allergen (NYSE: AGN) with a Buy rating and a price target of $350.00.

Analyst Shibani Malhotra commented, "We initiate coverage of Allergan Plc (AGN) with a Buy rating and $350 target price based on our sum-of-the-parts DCF analysis. Allergan is run by one... More

Allergan (AGN) Updates on H215 Outlook; Reflects Divestiture of Global Genetics Unit

Allergan (NYSE: AGN)\ announced its updated second-half 2015 continuing operations financial forecast. The forecast reflects adjustments for the upcoming expected discontinued operations as a result of the previously announced divestiture of its Global Generics business to Teva Pharmaceuticals (NYSE: TEVA). The Company intends to begin reporting its Global Generics business as discontinued operations with its third quarter 2015 results. The transaction with Teva is expected to close in the first quarter of 2016.

Continuing operations includes the... More

Democrats take aim at drug prices, prompting sharp drops in biotech stocks

By Ransdell Pierson and Bill Berkrot

(Reuters) - Democratic lawmakers on Monday attacked "massive" price increases of two heart drugs by Canada's Valeant, fueling a rout in drugmaker shares on worries of a government and insurer clampdown on U.S. drug prices.

All 18 Democratic members of the House of Representatives Committee on Oversight and Government Reform urged their chairman to subpoena Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) and force it to provide documents relating to price increases of 212 percent for Isuprel and 525 percent for Nitropress. Valeant... More

Allergan (AGN) Launches Generic INVEGA

Allergan plc (NYSE: AGN) launched a generic version of Janssen's INVEGA the U.S. Allergan is the first company to receive FDA approval for and launch a generic version of INVEGA®, demonstrating the deep expertise of the Company's global generics R&D, regulatory and... More